

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 February 2025 (13.02.2025)



(10) International Publication Number
WO 2025/035066 A1

(51) International Patent Classification:

A61K 31/4184 (2006.01) *A61K 45/06* (2006.01)
A61K 9/20 (2006.01) *C07D 235/30* (2006.01)

(21) International Application Number:

PCT/US2024/041649

(22) International Filing Date:

09 August 2024 (09.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/518,859 10 August 2023 (10.08.2023) US

(71) Applicant: **BIOHAVEN THERAPEUTICS LTD.**
[US/GB]; Ritter House, P.O. Box 173 Road Town, 1110 Tortola (VG).

(72) Inventors: **KUMAR, Rajesh**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT 06510 (US). **REKA, Ajaya, Kumar**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT 06510 (US). **LAKKARAJU, Jhansi**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT 06510 (US). **HS, Raghuchandan**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT 06510 (US). **BURUJU, Pavitra**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT 06510 (US). **SEVINSKY, Heather, Johnson**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT 06510 (US).

(74) Agent: **LECUYER, Karen, A.** et al.; 25 W. Main Street, Suite 800, Madison, WI 53703 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,


KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: EXTENDED-RELEASE FORMULATIONS OF Kv7.2/7.3 POTASSIUM CHANNEL ACTIVATORS



I

(57) Abstract: Described herein are solid, oral extended-release Kv7.2/7.3 potassium channel activator formulations. In certain aspects, the formulations have specified dissolution profiles and/or specified peak to trough ratios. In an aspect, the formulation includes an intragranular portion including the Kv7.2/7.3 potassium channel activator, a hydrophilic matrix polymer, a filler, and a binder; and an extragranular portion including an extended-release polymer, optionally a hydrophilic matrix polymer, and a lubricant. The Kv7.2/7.3 potassium channel activator is of Formula I or a pharmaceutically acceptable salt thereof.



WO 2025/035066 A1